Repare Therapeutics Inc

Repare Therapeutics is a clinical-stage biotechnology company whose business model relies on animal testing as a core component of its drug discovery and development process. The company's pipeline of precision oncology therapeutics, which targets DNA damage response pathways, requires extensive preclinical testing in animal models to evaluate efficacy and safety before advancing to human clinical trials. This standard industry practice is integral to its research collaboration and licensing agreements, such as its 2019 partnership with Ono Pharmaceutical Co., Ltd. to develop products targeting DNA Polymerase θ.

As a pharmaceutical research entity, Repare Therapeutics conducts these activities to satisfy regulatory requirements for investigational new drug applications. The use of animals in this context constitutes commercial exploitation under the firm's exclusion policy, as the activity is conducted for the purpose of developing and commercializing products. The evidence gathered is limited to contractual and corporate filings that confirm the company's operational structure but do not detail the specific scale or nature of its animal testing. This lack of public, granular disclosure regarding animal use is typical for early-stage biotech firms but results in an evidence gap for a more detailed narrative on the volume or conditions of such testing.